Core Viewpoint - China Biopharmaceutical (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3122, a PARP1 inhibitor, from the National Medical Products Administration (NMPA) in China, aimed at treating advanced malignant tumors [1] Group 1: Drug Development - TQB3122 is a highly selective PARP1 inhibitor with the ability to penetrate the blood-brain barrier, utilizing a dual mechanism to exert anti-tumor effects [1] - The drug competitively inhibits the catalytic activity of the PARP1 enzyme, blocking DNA single-strand break repair, and stabilizes the DNA-PARP complex to hinder replication fork progression [1] - TQB3122 selectively targets and kills tumor cells with BRCA mutations or homologous recombination deficiencies based on the principle of "synthetic lethality" [1] Group 2: Clinical Potential - Research indicates that TQB3122 shows significant efficacy across multiple tumor models and has outstanding distribution capabilities in brain tissue, making it a potential new option for treating intracranial tumors [1] - Currently, there are no approved drugs targeting the same pathway globally, positioning TQB3122 as a novel therapeutic choice for patients with advanced solid tumors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 目前，全球尚無同靶點藥物獲批上市。本集團將探索TQB3122在晚期實體瘤中的安全性與療效，有 望為全球患者提供新的治療選擇。 承董事會命 中國生物製藥有限公司 主席 謝其潤 香港，二零二五年八月十一日 1 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQB3122「PARP1抑制劑」臨床試驗申請獲NMPA受理 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQB3122「PARP1抑制劑」的新藥臨床試驗申請(IND)已獲得中國國家藥品監督管理局 (NMPA)受理，擬用於治療晚期惡性腫瘤。 TQB3122是一款具有高選擇性和血腦屏障穿透能力的PARP1抑制劑，通過雙重機制發揮抗腫瘤作 用：一方面，競爭性抑制PARP1酶的催化活性，阻斷DNA單鏈斷裂修復；另一方面，通過 ...

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [35] Core Viewpoints - The report emphasizes the importance of multi-party collaboration in supporting the development of innovative drugs and medical devices, highlighting the integration of data, policy, and funding as essential elements for growth [4] - The report notes that recent measures from the Financial Supervisory Administration and the Medical Insurance Bureau aim to promote the development of commercial health insurance, which will provide additional support for the innovation and development of drugs and medical devices [4] Summary by Sections Industry Insights - The Medical Insurance Bureau's recent meetings have established a comprehensive support system for innovative drugs and medical devices, involving various stakeholders such as research institutions, enterprises, medical institutions, financial companies, and government departments [4] - The Financial Supervisory Administration has released measures to enhance the quality of commercial health insurance, which will further support the biopharmaceutical industry's innovation [4] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as 恒瑞医药 (Hengrui Medicine), 百济神州 (BeiGene), and 中国生物制药 (China Biologic Products) [6] - It also highlights companies with significant single-product potential and those leading in advanced technology platforms, recommending关注 (focus on) companies like 凯莱英 (Kailaiying) and 药明康德 (WuXi AppTec) [6] Market Performance - The pharmaceutical sector experienced a decline of 0.84% last week, ranking last among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.23% [9][21] - The report indicates that the pharmaceutical sector's valuation is currently at 30.91 times (TTM), with a premium of 37.32% compared to the overall A-shares excluding financials [27]

港股三大指数今日高开，盘初小幅探底后再度回升转涨，恒生指数涨0.19%，国企指数平收，恒生科技 指数上涨0.11%，总体呈现窄幅震荡行情。 3）技术面与拥挤度 年内板块显著跑赢，H股生物科技/创新药年内涨幅可观，存在筹码拥挤、获利盘多的情况，而方法学落 地恰逢技术性回撤窗口。 短期来看，主要是编制规则落地引发的被动波动与情绪反馈，并非行业景气的反转信号。被剔除标的仍 面临被动资金再平衡的供给压力，而留下/新纳入的"纯创新药"标的相对更具被动增配的支撑。 ETF方面，港股创新药精选ETF（520690）盘中持续震荡，截至发稿，成交额破6000万，换手率近 20%，持续溢价，买盘强烈。成分股中超半数上涨，晶泰控股涨超5%；药明合联涨超4%；复星医药、 药明康德、乐普生物-B、和黄医药等个股跟涨，涨幅均超2%。 相关机构发文表示，早盘（约10:30）恒生港股通创新药指数一度下跌约2.4%；而资金逆势"抢筹"，恒 生创新药相关ETF盘中获净申购1000万份。 创新药早盘跳水更像是规则落地+拥挤度消化下的回调，而不是主线终结。等被动抛压释放后，"纯度 更高"的创新药篮子反而有望为中期资金提供更清晰的配置锚。 原因如下： ...

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Chengdu Tianqing, has received approval for its biosimilar Adalimumab (Taibowei) in Algeria, providing affordable treatment options for patients with autoimmune diseases in Belt and Road Initiative countries [1][2] Group 1: Product Approval and Market Impact - The approval of Taibowei marks a significant step in meeting the growing demand for high-quality biosimilars in Algeria, a key market in North Africa [2] - Adalimumab is a critical drug for treating various autoimmune diseases, including rheumatoid arthritis and psoriasis [1] - The successful approval reflects the company's commitment to innovation and internationalization, aligning with the Belt and Road Initiative [2] Group 2: Regulatory and Quality Management - The development of biosimilars requires demonstrating high similarity in quality, safety, and efficacy to the reference drug, with China's regulatory framework evolving since 2015 [1] - As of 2024, over 20 biosimilars have been approved in China, with Taibowei being a successful example of this process [1] - The company has established large R&D and production bases in Jiangsu, with multiple production lines certified by EU cGMP and US FDA, emphasizing the importance of quality management [1] Group 3: Future Strategy and Collaboration - The company plans to deepen collaboration with local partners in Algeria to accelerate the commercialization of its products [2] - The firm aims to leverage its established technology platform and existing biosimilars to support further international expansion [2] - Future efforts will focus on innovation and meeting clinical needs in Belt and Road countries, contributing to the "Health Silk Road" initiative [2]

Group 1 - The innovative drug sector is experiencing volatility, but market enthusiasm for investment remains strong, as evidenced by the high trading volume of the Hang Seng Innovative Drug ETF (520500) [1] - The Hang Seng Innovative Drug ETF has seen a continuous inflow of funds for three consecutive trading days, with its latest share count and scale reaching 597 million shares and 1.155 billion yuan, respectively, marking a growth of over 136% in the last three months [1][2] - The Hang Seng Innovative Drug Index has been revised to exclude CXO industry companies, focusing on pharmaceuticals and biotechnology, which enhances the index's purity and aligns it more closely with core industry drivers [1][2] Group 2 - The Hang Seng Innovative Drug Index now consists of 29 constituent stocks, all from Hong Kong, showcasing high-growth potential innovative drug companies, which adds to its investment value [2] - Recent updates from the National Healthcare Security Administration indicate that several newly included domestic innovative drugs are rapidly entering hospitals, suggesting future catalysts for the innovative drug sector [2] - The Hang Seng Innovative Drug ETF (520500) is managed by Huatai-PB Fund, which has over 18 years of ETF operation experience, further enhancing investor confidence [2][3] Group 3 - The innovative drug sector is showing signs of fundamental improvement driven by innovation and policy support, with the Hang Seng Innovative Drug Index's purity and growth potential expected to increase further [3] - The liquidity and T+0 trading support of the Hang Seng Innovative Drug ETF (520500) make it an attractive option for investors looking to capitalize on the accelerating opportunities in the innovative drug sector [3]

Group 1 - The core viewpoint of the news is that the recent decline in innovative pharmaceuticals is seen as a technical correction after a rapid increase, with long-term support expected from domestic policies and international recognition of value [1][3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced significant capital inflows, totaling 471 million yuan over the past four days and 715 million yuan over the past ten days, indicating strong investor interest despite recent price declines [1][4] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has outperformed other indices, with a cumulative increase of 101.58% year-to-date, significantly exceeding the Hang Seng Index and Hang Seng Tech Index by 78.08 and 79.53 percentage points, respectively [6][7] Group 2 - Institutions believe that the innovative drug sector will undergo a value reassessment, supported by domestic engineer advantages, abundant clinical resources, and favorable policies, leading to improved profitability for domestic innovative drug companies [3][4] - The National Healthcare Security Administration's confirmation of a new pricing mechanism for newly listed drugs is expected to provide higher pricing flexibility and efficiency for high-quality innovative drugs, enhancing cash flow returns for manufacturers [3][4] - The innovative drug industry is entering a 2.0 era, with expectations of deeper participation in the global market over the next decade, supported by a virtuous cycle of cash inflows benefiting research and development [3][4]

8月11日，创新药连续第3日回调，创新药"新势力"港股通创新药ETF（520880）场内价格一度跌近 2%，现跌1.18%，盘中持续宽幅溢价，实时溢价率0.68%，显示买盘资金逢跌积极介入。 拉长时间看，港股通创新药ETF（520880）持续吸金，上交所数据显示，其近4日连续获资金净流入合 计4710万元，近10日资金更是累计增仓7.15亿元。 | 分时 多日 1分 · | | | | | F9 盘前盘后 叠加 九砖 画线 工具 (2 >> | | | | | | 港股通创新药ETF O 37 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 13222 | | | | 520880[港股通创新药ETF] 10:21 价 1.176 涨跌 -0.014(-1 -- 2.70% | | E | | 1.176 -0.014 -1.18% | | | | N 520880 | | 1.206 | | | | | | 135% | | SSE CNY 10:21:22 交易中 | | | | T ...

Market Overview - The Hong Kong stock market rebounded last week, with the Hang Seng Index rising 1.4% to close at 24,858 points and the Hang Seng Tech Index increasing 1.2% to 5,460 points. The average daily trading volume decreased by 22.1% week-on-week to over 226.5 billion HKD, while net inflow from the Stock Connect was 21.7 billion HKD. All 12 major sectors in the Hong Kong stock market saw gains, with the materials sector surging 11.0% and the healthcare sector rising only 0.1%, the lowest performer [1]. Earnings Expectations - Current earnings expectations for Hong Kong stocks remain robust, with projected earnings growth rates of 2.7% and 8.5% for 2025 and 2026, respectively. The upstream resources sector benefits from anti-involution policies, coupled with stabilization in the Chinese bond market supporting earnings upgrades. However, short-term valuations have significantly recovered, with the Hang Seng Index's forecast PE returning to mid-range levels of 2018-2019, leading to a high-level consolidation phase in the market [1]. Sector Performance - The automotive sector saw a counter-trend increase last week, with new energy vehicle stocks like Li Auto and NIO rising 1%-3%. Dongfeng Motor surged 22.8% due to domestic anti-involution policies and potential state-owned enterprise restructuring news, outperforming its peers [3]. Industry Dynamics - The environmental, photovoltaic, wind power, natural gas, and electric equipment sectors have shown relative outperformance against the market, with average leads of 1.0%, 2.2%, 0.2%, 17.0%, and 2.2% percentage points, respectively, as of July 31. Conversely, the thermal power, nuclear power, and water supply sectors lagged behind by 0.6%, 6.1%, and 0.5% percentage points, respectively [4]. Power Generation Sector - The thermal power sector is expected to be impacted by rising coal prices, with July coal prices showing a narrowing year-on-year decline. The seasonal increase in coal demand has led to a month-on-month rise in prices, while coal inventories at major ports have decreased [5]. Electric Equipment Sector - The launch of the Yarlung Tsangpo River hydropower project, with a total investment of 1.2 trillion RMB and an expected capacity of 60-70 GW, is anticipated to significantly boost the national hydropower capacity. However, the long construction period may limit short-term profitability for related electric equipment manufacturers, who may face challenges in passing on rising costs to investors [6]. Photovoltaic Sector - As of July 30, the average price of polysilicon rose to 4.94 USD/kg, reflecting a year-on-year increase of 13.3% and a month-on-month increase of 17.1%. In contrast, the average price of photovoltaic modules decreased by 22.4% year-on-year, indicating that downstream demand needs to strengthen to confirm the price increases in polysilicon [7]. Stock Recommendations - Harbin Electric (1133 HK) is positioned to benefit from the Yarlung Tsangpo project, with a projected 95.0% year-on-year increase in net profit for the first half of 2025. Hong Kong and China Gas (1083 HK) expects moderate growth in natural gas sales, with a projected dividend yield of 4.8% for FY25. Cheung Kong Infrastructure (1038 HK) is stable in its operations across public utilities in the UK and Australia/New Zealand, also projecting a 4.8% dividend yield for FY25 [8]. Pharmaceutical Sector - The healthcare sector has shown strong performance, with the Hang Seng Healthcare Index rising 22.8% last month, outperforming the Hang Seng Index by nearly 20 percentage points. Policy support for innovative drug development and successful overseas collaborations for Chinese pharmaceutical companies have contributed to this growth [10]. Policy Developments - The government plans to establish a new directory for innovative drugs and support the use of medical insurance data for drug development, which is expected to enhance the sales of high-priced innovative drugs and accelerate research and development processes [11]. Drug Procurement Policy - The latest drug procurement policy is expected to trend towards moderation, allowing medical institutions to select brands for procurement, which may benefit high-quality products. The new rules aim to ensure that the lowest bids are reasonable and not below cost, thus maintaining the quality of procured drugs [12]. Key Individual Stocks - China Biologic Products (1177 HK) is projected to achieve double-digit growth in product sales revenue for 2025, bolstered by a significant milestone payment from Merck. Haijia Medical (6078 HK) is expected to benefit from the easing of government policies regarding medical insurance, which may improve its operating environment [13].

Core Viewpoint - China National Pharmaceutical Group (01177) experienced a decline of 4.48% in stock price, trading at 7.03 CNY per share with a transaction volume of 303 million CNY as of 10:10 AM on August 11 [1] Group 1: Company Overview - China National Pharmaceutical Group is an innovative research and development-driven pharmaceutical company, focusing on drug research, intelligent manufacturing, and sales [1] - The company specializes in various biological and chemical drugs, particularly excelling in four therapeutic areas: oncology, liver diseases, respiratory systems, and surgical/pain management [1] - Since its listing in 2000, the company has been included in multiple indices such as the MSCI Global Standard Index and the Hang Seng Index, and has been recognized in the "Top 50 Global Pharmaceutical Companies" by Pharmaceutical Manager for six consecutive years [1] Group 2: Financial Performance - As of the 2024 annual report, China National Pharmaceutical Group reported total revenue of 28.866 billion CNY and a net profit of 3.5 billion CNY [1] - The revenue contribution from the company's products has been increasing year by year [1] Group 3: Upcoming Events - The company is set to disclose its mid-year report for the fiscal year 2025 on August 18 [1]